Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Table 2 Efficacy results at week 26 (FAS, LOCF)

Efficacy parameter	Change from baseline		Difference vs. placebo (95% CI)	P value
Efficacy parameter	Placebo (n = 63)	Rasagiline 1 mg (n = 64)	Difference vs. placebo (95% CI)	P value
Primary efficacy
UPDRS total score	-0.18 ± 0.98	−3.18 ± 0.95	− 3.00 (− 5.62 to − 0.38)	0.025
Secondary efficacy
UPDRS part I	0.08 ± 0.15	− 0.54 ± 0.15	−0.62 (− 1.03 to − 0.21)	0.003
UPDRS part II	0.25 ± 0.38	−0.43 ± 0.37	−0.67 (− 1.70 to 0.35)	0.196
UPDRS part III	−0.52 ± 0.68	− 2.23 ± 0.65	− 1.71 (− 3.52 to 0.10)	0.064
Exploratory efficacy
Percent responders^a	42 (66.7)	51 (79.7)		0.051
Odds ratio (95% CI)	2.55 (1.00 to 6.54)
CGI-S score	0.08 ± 0.08	0.04 ± 0.08	−0.04 (− 0.25 to 0.17)	0.699
CGI-I score	3.88 ± 0.11	3.68 ± 0.11	− 0.20 (− 0.50 to 0.10)	0.196

Data are mean ± standard error of the mean or n (%).
^a Responders with worsening of < 3 points in UPDRS total score. CGI-I, Clinical Global Impressions Scale-Improvement; CGI-S, Clinical Global Impressions Scale-Severity; CI, confidence interval; UPDRS, Unified Parkinson’s Disease Rating Scale

ISSN: 2047-9158